1 Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology Pediatric Advisory Committee Meeting February 15, 2005 Barbara Hill, Ph.D. Division.

Slides:

Advertisements

Similar presentations

Role of Vitamin D in Blood Malignancies Dr Imran Hilal.

Advertisements

Endocrinologic and Metabolic Drugs Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Preclinical and Clinical Cardiac Safety Considerations Jeri.

Evaluation of a potential mutagenic MOA based on analysis of the weight of evidence and using the modified Hill criteria Martha M. Moore, Ph.D. Director,

Page 1 1 FDA Advisory Committee Meeting “Safety Considerations in the Development of Ultrasound Contrast Agents” June 24, 2008 Nonclinical Development.

Regulatory Toxicology James Swenberg, D.V.M., Ph.D.

Nonclinical Pharmacology/ Toxicology Data for PROTOPIC  (Tacrolimus ointment for Atopic Dermatitis) Barbara Hill, Ph.D. Division of Dermatologic and Dental.

Chemical Carcinogens – workplace risk assessment and health surveillance Tiina Santonen Paide.

1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.

6/14/2012FDA/CVM 1 Tong Zhou, Ph.D., DABT Division of Human Food Safety Office of New Animal Drug Evaluation Center for Veterinary Medicine US Food and.

Pediatric Subcommittee of the AIDAC October 29-30, 2003 Topical Immunosuppressants Bindi M. Nikhar, M.D., FAAP Division of Dermatologic and Dental Drug.

What Do Toxicologists Do?

Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.

Preclinical – Animal Study

TREATMENT OF OCCUPATIONAL SKIN DISEASES Antti I. Lauerma, M.D., Ph.D. FIOH.

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

Nonclinical Overview: CNS Toxicity with Rimonabant Endocrinologic & Metabolic Drugs Advisory Committee June 13, 2007 Karen Davis-Bruno, Ph.D. Division.

June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.

Smallpox Vaccine Contraindications and Screening Department of Health and Human Services Centers for Disease Control and Prevention December 2002 Note:

1 11/8/00 Pharmacology of Tacrolimus Ointment William Fitzsimmons, Pharm.D. Vice President Drug Development Project Management Fujisawa Healthcare, Inc.

1 Advisory Committee Meeting, 15 February, FDA Perspective Topical Immunosuppressants Bindi Nikhar, MD. Division of Dermatologic and Dental Drugs.

Disease –Modifying Antirheumatic Drugs ( DMARDs) Slow Acting Anti-inflammatory Drugs.

Guidance for Industry M4S: The CTD-Safety

Treatment Evaluation of HTLV infection treatment of asymptomatic HTLV carriers is not indicated.

Cancer Biology Ms. Sneha Singh Department of Zoology, DAVCG, Yamunanagar.

IND-Enabling Safety Studies for Rare Diseases

1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,

28/05/12 Questions (Rispondete alle domande che seguono usando il colore rosso per il testo) Tossicologia - Rubbiani Maristella.

TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Exploratory IND Studies

Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.

Clinical Review of Protopic Safety, Potential Risk, and Efficacy Martin M. Okun, M.D., Ph.D. Lisa Mathis, M.D. Division of Dermatologic and Dental Drug.

CA-1 Preclinical Studies Philip Bentley, PhD Vice President Toxicology/Pathology Novartis Pharmaceuticals Corporation Philip Bentley, PhD Vice President.

Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.

Laboratory toxicology. Toxicological methods In vitro –Cell cultures –Cell-free systems –Mechanistic In vivo (lab animals) –Acute –Subchronic –Chronic.

Elizabeth Gorevski Kingsbrook Jewish Medical Center Brooklyn, NY.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.

1 Assessing Cancer Risk & Assuring Safe Use of Topical Immunosuppressants: Recent History Susan K. Cummins, MD, MPH Medical Team Leader OCTAP and OPT.

Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post-exposure Prophylaxis Indication Using the Animal Rule.

1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.

Atopic Dermatitis: Disease Impact and Therapy

Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.

Lymph is the clear interstitial fluid found between the cells of the body. It enters the lymph vessels by filtration travels to one of the lymph nodes.

BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.

CCEB October 30 David J. Margolis MD PhD Associate Professor of Dermatology and Epidemiology Center for Clinical Epidemiology and Biostatistics University.

Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.

Furan-Induced Cytotoxicity, Cell Proliferation, and Tumorgenicity in Mouse Liver Dr. Glenda Moser.

The Future of Chemical Toxicity Testing in the U.S.

Pediatric Subcommittee of the AIDAC October 29-30, Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology October 30, 2003 Barbara.

Disease modified Anti-rheumatic drugs ( DMARD)

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

CS-1 Elidel ® (pimecrolimus) Cream 1% Safety Update Feb, 2005 Thomas Hultsch, MD Senior Medical Director Novartis Pharmaceuticals Corporation Thomas Hultsch,

QSAR in CANCER ASSESSMENT PURPOSE and AGENDA Gilman Veith Duluth MN May 19-21, 2010.

 DDT is a synthetic chemical compound once used widely in US and throughout the world as pesticide- a chemical substance used to kill weeds, insects,

Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products – Case Studies Anne M. Pilaro, Ph.D. DBOP/OODP/CDER Oncology Drugs.

James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Acute Toxicity Studies Single dose - rat, mouse (5/sex/dose), dog, monkey (1/sex/dose) 14 day observation In-life observations (body wt., food consumption,

Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

The process of drug development. Drug development 0,8 – 1 mld. USD.

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.

Novel Transcription Factor Inhibitor as Treatment for Epithelial Cell Cancers John Bushweller, Department of Molecular Physiology and Biological Physics,

ID DB08935 OBINUTUZUMAB C6512H10060N1712O2020S kDa CATEGORY

Eucrisa™ - Crisaborole

Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.

In effect, the modes of action of these 2 types of chemical carcinogens are more complex: genotoxic carcinogens may also exert epigenetic effects and nongenotoxic.

Positive Genetox Findings on a Candidate Pharmaceutical…. Now What

Presentation transcript:

1 Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology Pediatric Advisory Committee Meeting February 15, 2005 Barbara Hill, Ph.D. Division of Dermatologic and Dental Drug Products

2 ObjectiveObjective Summarize the animal toxicology data available for two topical immunosuppressants (Calcineurin Inhibitors) that have been approved for the topical treatment of atopic dermatitis Protopic (tacrolimus) ointment ( ) and Elidel (pimecrolimus) cream ( ) Summarize the animal toxicology data available for two topical immunosuppressants (Calcineurin Inhibitors) that have been approved for the topical treatment of atopic dermatitis Protopic (tacrolimus) ointment ( ) and Elidel (pimecrolimus) cream ( )

3 OutlineOutline StructuresStructures General ToxicologyGeneral Toxicology Genetic Toxicology StudiesGenetic Toxicology Studies Carcinogenicity StudiesCarcinogenicity Studies 9 Month Oral Monkey Toxicology Study9 Month Oral Monkey Toxicology Study SummarySummary StructuresStructures General ToxicologyGeneral Toxicology Genetic Toxicology StudiesGenetic Toxicology Studies Carcinogenicity StudiesCarcinogenicity Studies 9 Month Oral Monkey Toxicology Study9 Month Oral Monkey Toxicology Study SummarySummary

4 StructuresStructures Tacrolimus Pimecrolimus

5 General Toxicology Potential immune target organs of toxicity identified in chronic rodent and nonrodent toxicology studies include thymus, lymph nodes and spleen Nonclinical toxicology study results indicate both compounds are classic immunosuppressive agents Potential immune target organs of toxicity identified in chronic rodent and nonrodent toxicology studies include thymus, lymph nodes and spleen Nonclinical toxicology study results indicate both compounds are classic immunosuppressive agents

6 Genetic Toxicology An appropriate battery of in vitro and in vivo genotoxicity tests were conducted for tacrolimus and pimecrolimus Tacrolimus and pimecrolimus were non-genotoxic An appropriate battery of in vitro and in vivo genotoxicity tests were conducted for tacrolimus and pimecrolimus Tacrolimus and pimecrolimus were non-genotoxic

7 Carcinogenicity Studies Tacrolimus Oral rat Oral mouse Dermal mouse (marketed formulation) Tacrolimus Oral rat Oral mouse Dermal mouse (marketed formulation) Pimecrolimus Oral rat Oral mouse Dermal rat (marketed formulation) Dermal mouse (ethanol - 13 week; special high dose studies)

8 Oral Carcinogenicity Studies - Lymphoma Signal a – mg/kg/day b – Multiple of human exposure based on maximum human AUC c – Inadequate systemic exposure after oral administration d – No Observed Effect Level DrugSpeciesDose a Factor b Result ProtopicRat39XNegative c ProtopicMouse53XNegative c ElidelMouse XLymphoma ElidelMouse XNOEL d

9 Dermal Carcinogenicity Studies - Lymphoma Signal DrugSpeciesDose a Factor b Result Protopic c Mouse3.526XLymphoma Protopic c Mouse1.110XNOEL Elidel c Rat10 d 3.3XNegative Elidel e Mouse2547XLymphoma Elidel e Mouse1017XNOEL Elidel e Mouse XLymphoma f a – mg/kg/day b – Multiple of human exposure based on maximum human AUC c – Final market formulation; d – Highest possible dose e – Dissolved in ethanol (13 week studies); f – After 8 weeks

10 Carcinogenicity Studies - Other Tumor Signal DrugRouteSpeciesDose a Factor b Result ElidelOralRat (M&F)1040XBT c ElidelOralRat (M)532XBT c ElidelOralRat (F)521XNOEL ElidelOralRat (M)11.1XNOEL Elidel d DermalRat2e2e 1.5XFCAT f a – mg/kg/day b – Multiple of human exposure based on maximum human AUC c – Benign Thymoma; d – Final marketed formulation e – Lowest dose tested; f – Follicular cell adenoma of the Thyroid

11 Lymphoma Mechanism Results of the rodent carcinogenicity studies indicate that systemic immunosuppression leads to lymphoma formation It is not clear if the mechanism of lymphoma formation is the same for rodents and humans Results of the rodent carcinogenicity studies indicate that systemic immunosuppression leads to lymphoma formation It is not clear if the mechanism of lymphoma formation is the same for rodents and humans

12 Oral monkey toxicology study Oral doses of 0, 15, 45 and 120 mg/kg/day pimecrolimus administered for 39 weeks High dose discontinued after 19 weeks due to mortality Immunosuppressive related lymphoproliferative disorder (IRLD) noted in all dose groups – IRLD frequently progresses to lymphoma Oral doses of 0, 15, 45 and 120 mg/kg/day pimecrolimus administered for 39 weeks High dose discontinued after 19 weeks due to mortality Immunosuppressive related lymphoproliferative disorder (IRLD) noted in all dose groups – IRLD frequently progresses to lymphoma

13 Oral monkey toxicology study IRLD signal Dose (mg/kg/day) IncidenceSignal appearance (weeks) 00/8N/A 151/ /87 a – /914 – 18 a – one animal

14 Oral monkey toxicology study IRLD was associated with lymphocryptovirus (Epstein Barr related virus) IRLD exhibited a dose dependent expression Opportunistic infections were noted in some animals in all dose groups Three of the high dose monkeys with IRLD had concurrent leukemia IRLD was associated with lymphocryptovirus (Epstein Barr related virus) IRLD exhibited a dose dependent expression Opportunistic infections were noted in some animals in all dose groups Three of the high dose monkeys with IRLD had concurrent leukemia

15 Oral monkey toxicology study A NOEL for IRLD was not established in this study Low dose is 31X MRHD based on AUC Mechanism of lymphoma formation appears to be the same for monkeys and humans It is unknown if the mechanism of leukemia formation is the same for monkeys and humans A NOEL for IRLD was not established in this study Low dose is 31X MRHD based on AUC Mechanism of lymphoma formation appears to be the same for monkeys and humans It is unknown if the mechanism of leukemia formation is the same for monkeys and humans

16 Oral monkey toxicology study Results from this study confirm that adequate systemic exposure to pimecrolimus could elicit lymphoma formation via a similar mechanism that has been established for tacrolimus in humans

17 SummarySummary Protopic (tacrolimus) ointment and Elidel (pimecrolimus) cream are topical immunosuppressants Neither tacrolimus or pimecrolimus exhibited a genotoxic signal Tumorigenicity exhibited by tacrolimus and pimecrolimus appears to be mediated by a non-genotoxic mechanism (i.e., immunosuppression) Protopic (tacrolimus) ointment and Elidel (pimecrolimus) cream are topical immunosuppressants Neither tacrolimus or pimecrolimus exhibited a genotoxic signal Tumorigenicity exhibited by tacrolimus and pimecrolimus appears to be mediated by a non-genotoxic mechanism (i.e., immunosuppression)

18 SummarySummary A lymphoma signal was evident in a dermal mouse carcinogenicity study conducted with tacrolimus ointment A lymphoma signal was evident in an oral mouse carcinogenicity study conducted with pimecrolimus A lymphoma signal was evident in the 13 week dermal mouse study conducted with pimecrolimus dissolved in ethanol A lymphoma signal was evident in a dermal mouse carcinogenicity study conducted with tacrolimus ointment A lymphoma signal was evident in an oral mouse carcinogenicity study conducted with pimecrolimus A lymphoma signal was evident in the 13 week dermal mouse study conducted with pimecrolimus dissolved in ethanol

19 SummarySummary Other tumor signals included: –Benign thymoma noted in the oral rat carcinogenicity study conducted with pimecrolimus –Follicular cell adenoma of the thyroid noted in the dermal rat carcinogenicity study conducted with pimecrolimus cream Other tumor signals included: –Benign thymoma noted in the oral rat carcinogenicity study conducted with pimecrolimus –Follicular cell adenoma of the thyroid noted in the dermal rat carcinogenicity study conducted with pimecrolimus cream

20 SummarySummary IRLD was noted in a 9 month oral monkey toxicology study conducted with pimecrolimusIRLD was noted in a 9 month oral monkey toxicology study conducted with pimecrolimus Biologic plausibility of lymphoma formation in local lymph nodes can not be ruled out at this time IRLD was noted in a 9 month oral monkey toxicology study conducted with pimecrolimusIRLD was noted in a 9 month oral monkey toxicology study conducted with pimecrolimus Biologic plausibility of lymphoma formation in local lymph nodes can not be ruled out at this time